Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)
- 1 April 1982
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 7 (2-3), 205-207
- https://doi.org/10.1007/bf00254550
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Clinical trial of VP 16–213 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group BCancer, 1980
- VP-16, Cyclophosphamide, Adriamycin and Cis-platinum (V:CAP-I) in Patients with Metastatic Adenocarcinoma of the LungTumori Journal, 1979
- VP-16-213 CHEMOTHERAPY FOR ADVANCED SQUAMOUS-CELL CARCINOMA AND ADENOCARCINOMA OF LUNG1978
- A Combination of Cyclophosphamide, Methotrexate, Vincristine and VP 16–213 (NSC 141 540) in the Treatment of Bronchogenic CarcinomaTumori Journal, 1977
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Mitosis-inhibiting natural products. 24. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxinJournal of Medicinal Chemistry, 1971